|
1
|
Chaffer CL and Weinberg RA: A perspective
on cancer cell metastasis. Science. 331:1559–1564. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Connolly R and Stearns V: Epigenetics as a
therapeutic target in breast cancer. J Mammary Gland Biol
Neoplasia. 17:191–204. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sandhu R, Roll JD, Rivenbark AG and
Coleman WB: Dysregulation of the epigenome in human breast cancer:
Contributions of gene-specific DNA hypermethylation to breast
cancer pathobiology and targeting the breast cancer methylome for
improved therapy. Am J Pathol. 185:282–292. 2015. View Article : Google Scholar
|
|
4
|
Karsli-Ceppioglu S, Dagdemir A, Judes G,
Ngollo M, Penault-Llorca F, Pajon A, Bignon YJ and Bernard-Gallon
D: Epigenetic mechanisms of breast cancer: An update of the current
knowledge. Epigenomics. 6:651–664. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Jiang WG, Watkins G, Douglas-Jones A,
Holmgren L and Mansel RE: Angiomotin and angiomotin like proteins,
their expression and correlation with angiogenesis and clinical
outcome in human breast cancer. BMC Cancer. 6:162006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Holmgren L, Ambrosino E, Birot O, Tullus
C, Veitonmäki N, Levchenko T, Carlson LM, Musiani P, Iezzi M,
Curcio C, et al: A DNA vaccine targeting angiomotin inhibits
angiogenesis and suppresses tumor growth. Proc Natl Acad Sci USA.
103:9208–9213. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Troyanovsky B, Levchenko T, Månsson G,
Matvijenko O and Holmgren L: Angiomotin: An angiostatin binding
protein that regulates endothelial cell migration and tube
formation. J Cell Biol. 152:1247–1254. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bratt A, Birot O, Sinha I, Veitonmäki N,
Aase K, Ernkvist M and Holmgren L: Angiomotin regulates endothelial
cell-cell junctions and cell motility. J Biol Chem.
280:34859–34869. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Filipowicz W, Bhattacharyya SN and
Sonenberg N: Mechanisms of post-transcriptional regulation by
microRNAs: Are the answers in sight? Nat Rev Genet. 9:102–114.
2008. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Liu M, Roth A, Yu M, Morris R, Bersani F,
Rivera MN, Lu J, Shioda T, Vasudevan S, Ramaswamy S, et al: The
IGF2 intronic miR-483 selectively enhances transcription from IGF2
fetal promoters and enhances tumorigenesis. Genes Dev.
27:2543–2548. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Carrington JC and Ambros V: Role of
microRNAs in plant and animal development. Science. 301:336–338.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lu J, Getz G, Miska EA, Alvarez-Saavedra
E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA,
et al: MicroRNA expression profiles classify human cancers. Nature.
435:834–838. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Schetter AJ, Okayama H and Harris CC: The
role of microRNAs in colorectal cancer. Cancer J. 18:244–252. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Feber A, Xi L, Luketich JD, Pennathur A,
Landreneau RJ, Wu M, Swanson SJ, Godfrey TE and Litle VR: MicroRNA
expression profiles of esophageal cancer. J Thorac Cardiovasc Surg.
135:255–260. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Iorio MV, Visone R, Di Leva G, Donati V,
Petrocca F, Casalini P, Taccioli C, Volinia S, Liu CG, Alder H, et
al: MicroRNA signatures in human ovarian cancer. Cancer Res.
67:8699–8707. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wu H, Zhu S and Mo YY: Suppression of cell
growth and invasion by miR-205 in breast cancer. Cell Res.
19:439–448. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sempere LF, Christensen M, Silahtaroglu A,
Bak M, Heath CV, Schwartz G, Wells W, Kauppinen S and Cole CN:
Altered microRNA expression confined to specific epithelial cell
subpopulations in breast cancer. Cancer Res. 67:11612–11620. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Iorio MV, Casalini P, Piovan C, Di Leva G,
Merlo A, Triulzi T, Ménard S, Croce CM and Tagliabue E:
microRNA-205 regulates HER3 in human breast cancer. Cancer Res.
69:2195–2200. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Nam EJ, Yoon H, Kim SW, Kim H, Kim YT, Kim
JH, Kim JW and Kim S: MicroRNA expression profiles in serous
ovarian carcinoma. Clin Cancer Res. 14:2690–2695. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Nagadia R, Pandit P, Coman WB,
Cooper-White J and Punyadeera C: miRNAs in head and neck cancer
revisited. Cell Oncol. 36:1–7. 2013. View Article : Google Scholar
|
|
22
|
Iorio MV and Croce CM: MicroRNAs in
cancer: Small molecules with a huge impact. J Clin Oncol.
27:5848–5856. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang YW, Shi DB, Chen X, Gao C and Gao P:
Clinicopathological significance of microRNA-214 in gastric cancer
and its effect on cell biological behaviour. PLoS One.
9:e913072014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Inoue T, Iinuma H, Ogawa E, Inaba T and
Fukushima R: Clinicopathological and prognostic significance of
microRNA-107 and its relationship to DICER1 mRNA expression in
gastric cancer. Oncol Rep. 27:1759–1764. 2012.PubMed/NCBI
|
|
25
|
Fei X, Qi M, Wu B, Song Y, Wang Y and Li
T: MicroRNA-195-5p suppresses glucose uptake and proliferation of
human bladder cancer T24 cells by regulating GLUT3 expression. FEBS
Lett. 586:392–397. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Huang Q, Gumireddy K, Schrier M, le Sage
C, Nagel R, Nair S, Egan DA, Li A, Huang G, Klein-Szanto AJ, et al:
The microRNAs miR-373 and miR-520c promote tumour invasion and
metastasis. Nat Cell Biol. 10:202–210. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yu F, Deng H, Yao H, Liu Q, Su F and Song
E: mir-30 reduction maintains self-renewal and inhibits apoptosis
in breast tumor-initiating cells. Oncogene. 29:4194–4204. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhang T, Zhang J, Cui M, Liu F, You X, Du
Y, Gao Y, Zhang S, Lu Z, Ye L, et al: Hepatitis B virus X protein
inhibits tumor suppressor miR-205 through inducing hypermethylation
of miR-205 promoter to enhance carcinogenesis. Neoplasia.
15:1282–1291. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Muratsu-Ikeda S, Nangaku M, Ikeda Y,
Tanaka T, Wada T and Inagi R: Downregulation of miR-205 modulates
cell susceptibility to oxidative and endoplasmic reticulum stresses
in renal tubular cells. PLoS One. 7:e414622012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhang G, Hou X, Li Y and Zhao M: miR-205
inhibits cell apoptosis by targeting phosphatase and tensin homolog
deleted on chromosome ten in endometrial cancer Ishikawa cells. BMC
Cancer. 14:440. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wang N, Li Q, Feng NH, Cheng G, Guan ZL,
Wang Y, Qin C, Yin CJ and Hua LX: miR-205 is frequently
downregulated in prostate cancer and acts as a tumor suppressor by
inhibiting tumor growth. Asian J Androl. 15:735–741. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kalogirou C, Spahn M, Krebs M, Joniau S,
Lerut E, Burger M, Scholz CJ, Kneitz S, Riedmiller H and Kneitz B:
MiR-205 is progressively down-regulated in lymph node metastasis
but fails as a prognostic biomarker in high-risk prostate cancer.
Int J Mol Sci. 14:21414–21434. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Levchenko T, Aase K, Troyanovsky B, Bratt
A and Holmgren L: Loss of responsiveness to chemotactic factors by
deletion of the C-terminal protein interaction site of angiomotin.
J Cell Sci. 116:3803–3810. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Levchenko T, Bratt A, Arbiser JL and
Holmgren L: Angiomotin expression promotes hemangioendothelioma
invasion. Oncogene. 23:1469–1473. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yi C, Troutman S, Fera D,
Stemmer-Rachamimov A, Avila JL, Christian N, Persson NL, Shimono A,
Speicher DW, Marmorstein R, et al: A tight junction-associated
Merlin-angiomotin complex mediates Merlin's regulation of mitogenic
signaling and tumor suppressive functions. Cancer Cell. 19:527–540.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ranahan WP, Han Z, Smith-Kinnaman W,
Nabinger SC, Heller B, Herbert BS, Chan R and Wells CD: The adaptor
protein AMOT promotes the proliferation of mammary epithelial cells
via the prolonged activation of the extracellular signal-regulated
kinases. Cancer Res. 71:2203–2211. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Arigoni M, Barutello G, Lanzardo S, Longo
D, Aime S, Curcio C, Iezzi M, Zheng Y, Barkefors I, Holmgren L, et
al: A vaccine targeting angiomotin induces an antibody response
which alters tumor vessel permeability and hampers the growth of
established tumors. Angiogenesis. 15:305–316. 2012. View Article : Google Scholar : PubMed/NCBI
|
